

File reference	W17FOI349
Key words	Ocriplasmin
Date of release	10/08/2017
Attachments	No

Freedom of Information Act Disclosure log - Reply Extract

You asked

We are working on a project to improve expenditure in eye departments. We are trying to understand the cost effectiveness of Ocriplasmin (Jetrea) treatment for vitreo-macular traction.

We would like to obtain data regarding the number of injections performed, and possibly cost, of this treatment in your Trust, should you have ever provided it.

The timeframe would be 01/01/2016 to 31/05/2017, if possible divided by month, otherwise just a total number will suffice.

Our reply

We have supplied 12 vials of Ocriplasmin between 1/1/16 and 31/5/17.